How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
JA Hill, SK Seo - Blood, The Journal of the American Society of …, 2020 - ashpublications.org
Adoptive immunotherapy using B-cell–targeted chimeric antigen receptor (CAR)-modified T
cells to treat hematologic malignancies is transforming cancer care for patients with …
cells to treat hematologic malignancies is transforming cancer care for patients with …
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients
MR Cook, CS Dorris, KH Makambi, Y Luo… - Blood …, 2023 - ashpublications.org
Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary
central nervous system lymphoma (SCNSL) are associated with short survival and represent …
central nervous system lymphoma (SCNSL) are associated with short survival and represent …
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper
I Los-Arcos, G Iacoboni, M Aguilar-Guisado… - Infection, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging
treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene …
treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene …
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China
T Chen, Y Liu, Y Wang, Q Chang, J Wu, Z Wang… - Journal of hematology & …, 2022 - Springer
Primary central nervous system lymphoma (PCNSL) is a type of central nervous system
restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell …
restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell …
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
T Siddiqi, X Wang, MS Blanchard, JR Wagner… - Blood …, 2021 - ashpublications.org
CD19-directed chimeric antigen receptor (CD19CAR) T-cell therapy has been successful in
treating several B-cell lineage malignancies, including B-cell non-Hodgkin lymphoma …
treating several B-cell lineage malignancies, including B-cell non-Hodgkin lymphoma …
Infectious complications of CAR T-cell therapy: a clinical update
AG Stewart, AS Henden - Therapeutic Advances in Infectious …, 2021 - journals.sagepub.com
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary treatment modality used to
treat haematological malignancies. Lymphocytes are engineered to produce CARs directed …
treat haematological malignancies. Lymphocytes are engineered to produce CARs directed …
Toxicities following CAR-T therapy for hematological malignancies
R Hernani, A Benzaquén, C Solano - Cancer Treatment Reviews, 2022 - Elsevier
Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patients with
relapsed/refractory hematological malignancies. Research is also extending to other …
relapsed/refractory hematological malignancies. Research is also extending to other …
Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a …
J Meng, XQ Wu, Z Sun, RD Xun, MS Liu, R Hu… - Frontiers in …, 2021 - frontiersin.org
Background Currently, three chimeric antigen receptor (CAR)-T cell products axicabtagene
ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the US …
ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the US …
New immunotherapeutic approaches for cancer treatment
A Kamrani, R Hosseinzadeh, N Shomali… - … -Research and Practice, 2023 - Elsevier
Neoplasms are a worldwide recognized non-contagious disease which has the most
mortality rate after cardiovascular diseases. For decades, there has been a vast amount of …
mortality rate after cardiovascular diseases. For decades, there has been a vast amount of …